SRR1797291
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.300
- SPERMATOGENESIS+0.300
- KRAS_SIGNALING_DN+0.250
- APICAL_SURFACE+0.140
- E2F_TARGETS+0.080
- MYC_TARGETS_V2+0.060
- ESTROGEN_RESPONSE_LATE-0.040
- HEDGEHOG_SIGNALING-0.040
- MYOGENESIS-0.050
- APICAL_JUNCTION-0.080
Top 10 suppressed
- PROTEIN_SECRETION-0.440
- TGF_BETA_SIGNALING-0.420
- ANGIOGENESIS-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- NOTCH_SIGNALING-0.390
- IL6_JAK_STAT3_SIGNALING-0.370
- PEROXISOME-0.370
- APOPTOSIS-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR650150 | — | — | 0.945 |
| 2 | SRR4195643 | — | — | 0.943 |
| 3 | SRR4195695 | — | — | 0.933 |
| 4 | TCGA-KQ-A41O-01A-12R-A352-07 | — | — | 0.925 |
| 5 | SRR12202488 | — | — | 0.923 |
| 6 | ERR4976605 | — | D | 0.921 |
| 7 | BS_J71N7D09 | medulloblastoma | — | 0.921 |
| 8 | MDT-AP-0325 | Med | Medulloblastoma | 0.913 |
| 9 | ERR4976613 | — | D | 0.911 |
| 10 | ERR4976603 | — | E | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 6 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |